alemtuzumab
cellectis ,sanofi
['cart,(-cartitude)', 'nhl', ' uc,(-ucsd),(-ucsf),', 'car t']
join at #eha2022 today, june 10th at 4:30pm cest, as we present two poster presentations on balli-01, evaluating ucart22 in r/r b-all and on ucart20x22, our first allogeneic dual car t-cell product candidate being developed for patients with r/r nhl. 
Cellectis is gene editing the first of its kind, off-the-shelf UCART immunotherapies to fight blood cancers. Community Guidelines: https://t.co/r6BQ1u1S6X